[Form 4] Clover Health Investments, Corp Insider Trading Activity
Anna U. Loengard, a director of Clover Health Investments, reported purchases of Class A common stock executed on 08/13/2025 and a reduction in previously reported beneficial ownership. The filing shows two custodial IRA purchases for the reporting person’s children: 12,000 shares at $2.60 and 14,500 shares at $2.59, held indirectly in a son’s and daughter’s IRA, respectively. The report also states the reporting person no longer has a reportable beneficial interest in 151,725 shares previously held by an ex-spouse. Following the transactions reported, Loengard beneficially owns 29,610 and 27,600 shares indirectly as noted.
Anna U. Loengard, membro del consiglio di Clover Health Investments, ha segnalato acquisti di azioni ordinarie di classe A eseguiti il 13/08/2025 e una riduzione di una precedente posizione detenuta a titolo di beneficiario. La comunicazione indica due acquisti tramite IRA custodia per i figli del dichiarante: 12.000 azioni a 2,60$ e 14.500 azioni a 2,59$, detenute indirettamente rispettivamente nell'IRA del figlio e in quella della figlia. Il documento precisa inoltre che il dichiarante non detiene più un interesse beneficiario segnalabile in 151.725 azioni precedentemente possedute da un ex coniuge. Dopo le operazioni riportate, Loengard detiene utilmente 29.610 e 27.600 azioni indirettamente, come indicato.
Anna U. Loengard, directora de Clover Health Investments, informó compras de acciones comunes Clase A ejecutadas el 13/08/2025 y una reducción de la participación beneficiosa previamente informada. La presentación muestra dos compras a través de IRA custodial para los hijos de la persona informante: 12.000 acciones a 2,60$ y 14.500 acciones a 2,59$, mantenidas indirectamente en la IRA del hijo y de la hija, respectivamente. El informe también indica que la persona informante ya no tiene un interés beneficioso reportable en 151.725 acciones que antes pertenecían a un excónyuge. Tras las transacciones notificadas, Loengard posee de forma beneficiosa 29.610 y 27.600 acciones de forma indirecta, según se señala.
안나 U. 롱가드는 Clover Health Investments의 이사로서 2025년 8월 13일에 집행된 클래스 A 보통주 매수와 이전에 보고된 실질적 소유 지분의 감소를 신고했습니다. 제출서류에는 신고자의 자녀들을 위한 두 건의 관리형 IRA 매수가 기재되어 있으며, 각각 자녀의 IRA에 간접 보유된 12,000주(주당 2.60달러)와 14,500주(주당 2.59달러)입니다. 또한 신고자는 이전 배우자가 보유했던 151,725주의 보고 대상 실질적 이익을 더 이상 보유하지 않음을 명시하고 있습니다. 보고된 거래 이후 롱가드는 문서에 표시된 대로 간접적으로 각각 29,610주 및 27,600주를 실질 보유하고 있습니다.
Anna U. Loengard, administratrice de Clover Health Investments, a signalé des achats d'actions ordinaires de classe A exécutés le 13/08/2025 et une réduction d'une participation bénéficiaire précédemment déclarée. Le dépôt indique deux achats via des IRA sous garde pour les enfants de la personne déclarante : 12 000 actions à 2,60$ et 14 500 actions à 2,59$, détenues indirectement dans l'IRA du fils et celle de la fille, respectivement. Le rapport précise également que la déclarante ne détient plus d'intérêt bénéficiaire déclarable sur 151 725 actions précédemment détenues par un ex-conjoint. Après les opérations rapportées, Loengard détient bénéficiairement et indirectement 29 610 et 27 600 actions, comme indiqué.
Anna U. Loengard, Direktorin von Clover Health Investments, meldete Käufe von Stammaktien Klasse A, ausgeführt am 13.08.2025, sowie eine Verringerung einer zuvor gemeldeten wirtschaftlichen Beteiligung. Die Einreichung weist zwei Käufe über verwahrte IRAs für die Kinder der meldenden Person aus: 12.000 Aktien zu 2,60$ und 14.500 Aktien zu 2,59$, die jeweils indirekt in der IRA des Sohnes bzw. der Tochter gehalten werden. Außerdem gibt der Bericht an, dass die meldende Person kein meldefähiges wirtschaftliches Interesse mehr an 151.725 Aktien besitzt, die zuvor ein Ex-Ehepartner hielt. Nach den gemeldeten Transaktionen besitzt Loengard wie angegeben indirekt wirtschaftlich 29.610 und 27.600 Aktien.
- Director-level insider reported purchases, showing continued family-directed accumulation of CLOV shares
- Purchases executed at low per-share prices ($2.59 and $2.60), adding a total of 26,500 Class A shares into custodial IRAs
- Reporting person no longer has beneficial interest in 151,725 shares previously included in prior ownership reports due to ex-spouse holdings
Insights
TL;DR: Director made small custodial purchases; previously reported indirect holdings were reduced due to change in marital status.
The Form 4 discloses routine open-market purchases executed by or for family-member custodial IRAs, not direct purchases by the director. The transactions are modest in size relative to typical institutional holdings and are recorded as indirect ownership. The filing also documents the removal of 151,725 shares from the director’s reportable holdings because those shares are now held by an ex-spouse. For governance review, this is an administrative update reflecting personal custody arrangements rather than a corporate governance action affecting board composition.
TL;DR: Two small purchases at ~$2.59–$2.60 per share recorded; net reportable beneficial interest decreased by 151,725 shares.
The reported purchases—12,000 shares at $2.60 and 14,500 shares at $2.59—represent minor additions held in custodial IRAs for family members and are logged as indirect ownership. There is no exercise of derivatives or other transactions reported. The material change is the removal of 151,725 shares from prior reported ownership due to transfer of those shares to an ex-spouse, which reduces previously disclosed beneficial exposure but does not indicate sales or market dispositions by the reporting person themselves.
Anna U. Loengard, membro del consiglio di Clover Health Investments, ha segnalato acquisti di azioni ordinarie di classe A eseguiti il 13/08/2025 e una riduzione di una precedente posizione detenuta a titolo di beneficiario. La comunicazione indica due acquisti tramite IRA custodia per i figli del dichiarante: 12.000 azioni a 2,60$ e 14.500 azioni a 2,59$, detenute indirettamente rispettivamente nell'IRA del figlio e in quella della figlia. Il documento precisa inoltre che il dichiarante non detiene più un interesse beneficiario segnalabile in 151.725 azioni precedentemente possedute da un ex coniuge. Dopo le operazioni riportate, Loengard detiene utilmente 29.610 e 27.600 azioni indirettamente, come indicato.
Anna U. Loengard, directora de Clover Health Investments, informó compras de acciones comunes Clase A ejecutadas el 13/08/2025 y una reducción de la participación beneficiosa previamente informada. La presentación muestra dos compras a través de IRA custodial para los hijos de la persona informante: 12.000 acciones a 2,60$ y 14.500 acciones a 2,59$, mantenidas indirectamente en la IRA del hijo y de la hija, respectivamente. El informe también indica que la persona informante ya no tiene un interés beneficioso reportable en 151.725 acciones que antes pertenecían a un excónyuge. Tras las transacciones notificadas, Loengard posee de forma beneficiosa 29.610 y 27.600 acciones de forma indirecta, según se señala.
안나 U. 롱가드는 Clover Health Investments의 이사로서 2025년 8월 13일에 집행된 클래스 A 보통주 매수와 이전에 보고된 실질적 소유 지분의 감소를 신고했습니다. 제출서류에는 신고자의 자녀들을 위한 두 건의 관리형 IRA 매수가 기재되어 있으며, 각각 자녀의 IRA에 간접 보유된 12,000주(주당 2.60달러)와 14,500주(주당 2.59달러)입니다. 또한 신고자는 이전 배우자가 보유했던 151,725주의 보고 대상 실질적 이익을 더 이상 보유하지 않음을 명시하고 있습니다. 보고된 거래 이후 롱가드는 문서에 표시된 대로 간접적으로 각각 29,610주 및 27,600주를 실질 보유하고 있습니다.
Anna U. Loengard, administratrice de Clover Health Investments, a signalé des achats d'actions ordinaires de classe A exécutés le 13/08/2025 et une réduction d'une participation bénéficiaire précédemment déclarée. Le dépôt indique deux achats via des IRA sous garde pour les enfants de la personne déclarante : 12 000 actions à 2,60$ et 14 500 actions à 2,59$, détenues indirectement dans l'IRA du fils et celle de la fille, respectivement. Le rapport précise également que la déclarante ne détient plus d'intérêt bénéficiaire déclarable sur 151 725 actions précédemment détenues par un ex-conjoint. Après les opérations rapportées, Loengard détient bénéficiairement et indirectement 29 610 et 27 600 actions, comme indiqué.
Anna U. Loengard, Direktorin von Clover Health Investments, meldete Käufe von Stammaktien Klasse A, ausgeführt am 13.08.2025, sowie eine Verringerung einer zuvor gemeldeten wirtschaftlichen Beteiligung. Die Einreichung weist zwei Käufe über verwahrte IRAs für die Kinder der meldenden Person aus: 12.000 Aktien zu 2,60$ und 14.500 Aktien zu 2,59$, die jeweils indirekt in der IRA des Sohnes bzw. der Tochter gehalten werden. Außerdem gibt der Bericht an, dass die meldende Person kein meldefähiges wirtschaftliches Interesse mehr an 151.725 Aktien besitzt, die zuvor ein Ex-Ehepartner hielt. Nach den gemeldeten Transaktionen besitzt Loengard wie angegeben indirekt wirtschaftlich 29.610 und 27.600 Aktien.
FAQ
What transactions did Anna U. Loengard report on Form 4 for CLOV?
How are the purchased CLOV shares held according to the filing?
Did the filing report any disposals or derivative transactions?
What is the reporting person’s relationship to CLOV?
On what date were the transactions executed?
